אגיסטן לכסניות ישראל - עברית - Ministry of Health

אגיסטן לכסניות

padagis israel agencies ltd, israel - clotrimazole - לכסניה - clotrimazole 10 mg - clotrimazole

בינוקריט 8000 יחבל  0.8 מל ישראל - עברית - Ministry of Health

בינוקריט 8000 יחבל 0.8 מל

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 8000 iu / 0.8 ml - erythropoietin

טפינלר 50 מג ישראל - עברית - Ministry of Health

טפינלר 50 מג

novartis israel ltd - dabrafenib as mesilate - קפסולה קשיחה - dabrafenib as mesilate 50 mg - dabrafenib

טפינלר 50 מג ישראל - עברית - Ministry of Health

טפינלר 50 מג

novartis israel ltd - dabrafenib as mesilate - קפסולה קשיחה - dabrafenib as mesilate 50 mg - dabrafenib

טפינלר 75 מג ישראל - עברית - Ministry of Health

טפינלר 75 מג

novartis israel ltd - dabrafenib as mesilate - קפסולה קשיחה - dabrafenib as mesilate 75 mg - dabrafenib

מקיניסט 0.5 מג ישראל - עברית - Ministry of Health

מקיניסט 0.5 מג

novartis israel ltd - trametinib as dimethyl sulfoxide - טבליות מצופות פילם - trametinib as dimethyl sulfoxide 0.5 mg - trametinib

מקיניסט 2 מג ישראל - עברית - Ministry of Health

מקיניסט 2 מג

novartis israel ltd - trametinib as dimethyl sulfoxide - טבליות מצופות פילם - trametinib as dimethyl sulfoxide 2 mg - trametinib

רקורמון 2000 IU ישראל - עברית - Ministry of Health

רקורמון 2000 iu

roche pharmaceuticals (israel) ltd - epoetin beta 2000 iu / 0.3 ml - solution for injection - erythropoietin - treatment of anemia associated with chronic renal failure (renal anemia) in patients on dialysis. treatment of symptomatic renal anemia in patients not yet undergoing dialysis. increasing the yield of autologous blood from patients in a pre-donation program. its use in this indication must be balanced against the reported increased risk of thromboembolic events. treatment should only be given to patients with moderate anemia (hb 10-13 g/dl (6.21- 8.07 mmol/l) no iron deficiency) or when blood conserving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). treatment of anemia in adult patients with solid tumors and treated with platinum-based chemotherapy prone to induce anemia (cisplatin 75 mg/m2/cycle carboplatin: 350 mg/m2/cycle). treatment of anemia in adult patients with multiple myeloma low grade non-hodgkin's lymphoma or chronic lymphocytic leukemia who have a relative

רקורמון IU 3000 ישראל - עברית - Ministry of Health

רקורמון iu 3000

roche pharmaceuticals (israel) ltd - epoetin beta 3000 iu / 0.3 ml - solution for injection - erythropoietin - treatment of anemia associated with chronic renal failure (renal anemia) in patients on dialysis. treatment of symptomatic renal anemia in patients not yet undergoing dialysis. increasing the yield of autologous blood from patients in a pre-donation program. its use in this indication must be balanced against the reported increased risk of thromboembolic events. treatment should only be given to patients with moderate anemia (hb 10-13 g/dl (6.21- 8.07 mmol/l) no iron deficiency) or when blood conserving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). treatment of anemia in adult patients with solid tumors and treated with platinum-based chemotherapy prone to induce anemia (cisplatin 75 mg/m2/cycle carboplatin: 350 mg/m2/cycle). treatment of anemia in adult patients with multiple myeloma low grade non-hodgkin's lymphoma or chronic lymphocytic leukemia who have a relative

רקורמון IU 5000 ישראל - עברית - Ministry of Health

רקורמון iu 5000

roche pharmaceuticals (israel) ltd - epoetin beta - תמיסה להזרקה - epoetin beta 5000 iu / 0.3 ml - erythropoietin - erythropoietin - treatment of anemia associated with chronic renal failure (renal anemia) in patients on dialysis. treatment of symptomatic renal anemia in patients not yet undergoing dialysis. increasing the yield of autologous blood from patients in a pre-donation program. its use in this indication must be balanced against the reported increased risk of thromboembolic events. treatment should only be given to patients with moderate anemia (hb 10-13 g/dl (6.21- 8.07 mmol/l) no iron deficiency) or when blood conserving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). treatment of anemia in adult patients with solid tumors and treated with platinum-based chemotherapy prone to induce anemia (cisplatin 75 mg/m2/cycle carboplatin: 350 mg/m2/cycle). treatment of anemia in adult patients with multiple myeloma low grade non-hodgkin's lymphoma or chronic lymphocytic leukemia who have a relative